Palisade Bio, Inc. (PALI) stock
PALINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.01−0.02 (-1.94%)
Close on Nov 17, 2026Market cap $176.01MP/E –Yield –
Palisade Bio price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Palisade Bio's price to sales ratio was 406.2× on Nov 11, 2026, against 41.3× a year earlier. Over the last 3 years it ranged from 14.8× to 468.7×, with a median of 90.0×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 406.2× | +391.3 |
| 2024 | Apr 30, 2024 | 14.9× | −6.8 |
| 2023 | Dec 29, 2023 | 21.7× | −24.5 |
| 2019 | Jul 31, 2019 | 46.2× | −9.8 |
| 2018 | Dec 31, 2018 | 56.0× | −410.7 |
| 2012 | Oct 31, 2012 | 466.7× | – |
See a number that looks wrong?